Evidence map›Paper›PMID 41285172›Full record

Trial reportThe Journal of infectious diseases2026

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial.

Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Julia A Lackenby, Noushin Jaberolansar, Jake O'Donnell, Vivian Kienzle and 18 more

Registry-linked trialAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05775887 (A PHASE 1 RANDOMIZED, ACTIVE-CONTROLLED, DOUBLEBLIND, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF AN ADJUVANTED SARS-CoV-2 UQSC2 PROTEIN SUBUNIT VACCINE IN HEALTHY ADULTS, AGED 18 TO 50 YEARS.), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05775887 phase1completednot on this map

A PHASE 1 RANDOMIZED, ACTIVE-CONTROLLED, DOUBLEBLIND, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF AN ADJUVANTED SARS-CoV-2 UQSC2 PROTEIN SUBUNIT VACCINE IN HEALTHY ADULTS, AGED 18 TO 50 YEARS.

TypeinterventionalSponsorThe University of QueenslandRan2023 to 2023Enrolled70ConditionsCOVID-19ArmsUQSC2 Vaccine, NVX-CoV2373 vaccine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Keith J ChappellSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0001-8636-5067
Francesca L MordantDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-3754-2642
Alberto A AmarillaSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-6640-3377
Naphak ModhiranSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0003-3205-4970
Benjamin LiangSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Zheyi LiDepartment of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Julia A LackenbySchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0003-0933-3998
Noushin JaberolansarThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Jake O'DonnellSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Vivian KienzleSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Varsha KommajosyulaThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Nicolas TardiotaThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Jillian K BennetIndependent consultant, Melbourne, Victoria, Australia.ORCID 0000-0002-1983-8642
Christina L HendersonSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-3374-6007
Rhiannon L DalrympleSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-2660-1424
Justin GohThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-4982-193X
Kym HogerThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Marianne GillardThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Martina L JonesThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0002-5154-6017
Karen HughesThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Ben HughesThe Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0009-0000-3289-2195
James BarnesWHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Patrick C ReadingDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.
Charani RanasingheDepartment of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.
Kanta SubbaraoDepartment of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria, Australia.
Trent P MunroSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.ORCID 0000-0003-1987-2020
Paul R YoungSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
Daniel WattersonSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.

Funding

Coalition for Epidemic Preparedness InnovationsNational Health and Medical Research Council of AustraliaQueensland Government
6 · The paper itself

Abstract

backgroundA coronavirus disease 2019 (COVID-19) subunit vaccine developed with the molecular clamp platform was among the first to enter clinical trials in 2020. While the vaccine was well suited to large-scale manufacture and demonstrated a favorable safety and immunogenicity profile, it did not progress into further clinical testing due to the human immunodeficiency virus 1 (HIV-1)-derived sequence in the molecular clamp, interfering with certain point-of-care HIV-1 diagnostic tests. A second-generation molecular clamp (MC2) has since been developed. Here, we describe a phase I clinical trial of an MC2-stabilized severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike subunit vaccine, UQSC2.

methodsA phase I, double-blind, active comparator-controlled trial was conducted in Australia (ClinicalTrials.gov NCT05775887). Healthy adults (aged 18-50 years), who had previously received ≥3 doses of an approved messenger RNA SARS-CoV-2 vaccine, received a single booster dose of either UQSC2 or the approved comparator NVX-CoV2373 (Nuvaxovid; Novavax) (n = 70; 35 per group). Safety, humoral immunogenicity (including against virus variants), and cellular immunogenicity were assessed through day 183. Cases of confirmed coronavirus disease 2019 (COVID-19) infection during the study were also examined.

resultsBoth vaccines were equally well tolerated and elicited comparable increases in neutralizing humoral responses against the vaccine-matched prototypic, Wuhan strain of SARS-CoV-2.

conclusionsUQSC2 was as well tolerated as the authorized comparator vaccine and produced an equally robust boost in neutralizing immune response. These findings support the effectiveness of the MC2 platform in producing vaccines against newly emerging variants of SARS-CoV-2 and other respiratory viruses, as well as the platform's potential use in emergency response to novel viruses.

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineSARS-CoV-2Spike Glycoprotein, CoronavirusAdolescentAdultAntibodies, NeutralizingAntibodies, ViralAustraliaDouble-Blind MethodFemaleHumansMaleMiddle AgedVaccines, SubunitAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Subunitclinical trialCOVID-19 vaccinemolecular clampphase ISARS-CoV-2severe acute respiratory syndrome coronavirus 2spike proteinvaccine platform

Identifiers

PMID41285172
PMCPMC13017720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.